Verastem, Inc. VSTM today announced the initiation of a Phase 1
dose-escalation study at Washington University to evaluate Verastem's
FAK inhibitor VS-6063 in combination with Merck's PD-1 inhibitor
pembrolizumab and gemcitabine in patients with pancreatic cancer. This
is the first of several combination clinical trials the Company expects
to initiate this year.
This Phase 1 clinical trial is anticipated to enroll approximately 50
patients and is being conducted at the Washington University School of
Medicine's Division of Oncology under the direction of Andrea
Wang-Gillam, MD, PhD, Clinical Director of the Gastrointestinal Oncology
Program.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in